BCNA often develops submissions to public consultations on issues of relevance to Australians affected by breast cancer. We also review and respond to government decisions or initiatives that are likely to affect our members.
- 2019 submissions and reviews
- 2018 submissions and reviews
- BCNA’s letter of support – Autologous Fat Grafting (November 2018)
- BCNA’s Letter of support – Programmed Death Ligand 1 (PD-L1) immunohistochemistry (IHC) testing for access to atezolizumab (Tecentriq®) (November 2018)
- BCNA’s letter of support – BRCA testing for talazoparib (October 2018)
- BCNA’s letter of support – Medicare Item Number for Breast PET (September 2018)
- Senate Community Affairs References Committee 2018 – My Health Record system (September 2018)
- Submission on the exposure draft of the Private Health Insurance (Reforms) Amendment Rules 2018 (August 2018)
- BCNA’s Letter of support – Medicare Item Number for Lymphoedema Services (July 2018)
- BCNA and Cancer Council’s letter - Changes to private health policy conditions – Clinical definitions consultation process (April 2018)
- Inquiry into the availability and accessibility of diagnostic imaging equipment around Australia (October 2017)
- Submission to the Department of Health on the draft National Palliative Care Strategy (September 2017)
- Submission to Department of Health public consultation on funding for private patients in public hospitals (September 2017)
- Submission to PBAC in support of goserelin (Zoladex) for premenopausal women (August 2017)
- Submission to the Productivity Commission: Reforms to Human Services Inquiry Draft Report (July 2017)
- Submission to NHMRC about new framework to guide funding of research (July 2017)
- Submission to the Senate Standing Committee on Community Affairs inquiry into the value and affordability of private health insurance (July 2017)
- Submission to PBAC in support of ribociclib (Kisqali) (June 2017)
- Submission to MSAC in support of Medicare funding for breast MRI for Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL) (June 2017)
- Submission to MSAC in support of Medicare funding for germline BRCA mutation testing to determine eligibility for Lynparza® (olaparib) (June 2017)
- Submission to The Parliamentary Joint Committee on Corporations and Financial Services inquiry into the Life Insurance Industry (March 2017)
- Palbociclib (Ibrance) to be considered for inclusion on the PBS (January 2017)
- Submission to MSAC in support of Medicare funding for Prosigna (PAM-50) Breast Cancer Prognostic Gene Signature Assay (December 2016)
- Submission to MSAC in support of Medicare funding for ovarian reserve tests (anti-Mullerian monitoring) and cryopreservation of ovarian tissue (July 2016)
- Submission to MSAC in support for Medicare funding for Oncotype DX breast cancer assay (July 2016)
- 2016 Federal Election Submission (May 2016)
- Submission to The Senate Economics Committee Inquiry into Scrutiny of Financial Advice - Accessing superannuation and insurance through the terminal illness provision (April 2016)
- Submission to Pharmaceutical Benefits Advisory Committee on tamoxifen for women at increased risk of breast cancer (February 2016)
- Australian Government Private Health Insurance Consultations 2015-16 (November 2015)
- Submission to the MBS Review Taskforce (November 2015)
- Parliamentary inquiry into availability of new cancer drugs (February 2015)
- Submissions to Pharmaceutical Benefits Advisory Committee (PBAC) on Kadcyla and Perjeta (October 2014)
- Inquiry into out-of-pocket costs of health care (May 2014)
- Submission to the Medical Services Advisory Committee (MSAC) on PET scans (March 2014)
- Submission to the Medical Services Advisory Committee (MSAC) in support of Targeted Intraoperative Radiotherapy (March 2014)
- Submission to the Medical Services Advisory Committee (MSAC) - Breast MRI (March 2014)
- Submissions to Pharmaceutical Benefits Advisory Committee (PBAC) on Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab) (February 2014)
- Submission to Medical Services Advisory Committee about expert second opinions on pathology results (November 2013)
- Submission to Pharmaceutical Benefits Advisory Committee (PBAC) in support of eribulin (October 2013)
- Federal Election 2013 Submission (July 2013)
- Submission to the Medical Services Advisory Committee on Oncotype DX (July 2013)
- Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) on trastuzumab emtansine (T-DM1) and everolimus (July 2013)
- Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) on three drugs for secondary breast cancer (February 2013)
- Submission to the Government about Single-Dose Stereotactic Radiosurgery (November 2012)
- Submission to the Government about DXA Scan Rebates (November 2012)
- Submission to the Pharmaceutical Benefits Advisory Committee for a new subsidy for women who have to take Herceptin before their surgery (June 2012)
- Submission to the Cancer Research Leadership Forum in response to their draft white paper, 'Towards a national cancer research plan' (May 2012)
- MRI rebates for young women with breast cancer (March 2012)
- NHMRC Statement on Thermal Imaging for Early Breast Cancer Detection (February 2012)
- Victorian Cancer (Reporting) Regulations 2012 (February 2012)
- Radiation Oncology Practice Standards options paper (September 2011)
- Personally Controlled Electronic Health Record System: Issues Paper (August 2011)
- Senate Inquiry into the PBS (July 2011)
- CHF Complementary Medicines Discussion Paper (July 2011)
- New Personally Controlled Electronic Health Record (PCEHR) system (June 2011)
- Improving elective surgery waiting times (May 2011)
- CHF Our Health, Our Communities Project (February 2011)
- Review of Transparency of the Therapeutic Goods Administration (TGA) August 2011)
- Senate inquiry into Patient Assisted Travel Schemes (last updated: February 2010)
- BreastScreen Australia Evaluation Report (last updated: November 2009)
- Submission to the Guiding Principles for Regional Cancer Centres (last updated: October 2009)
- Senate inquiry into gene patents (last updated: September 2011)